A double-blind, placebo-controlled trial in 93 children, aged 6-15 years, and with functional abdominal pain (Rome III criteria). The interventions were a chewable tablet with L. reuteri DSM 17938 at a dose of 10^8 cfu/day (n=47) or the equivalent placebo tablet (n=46), once daily. The intervention period was 4 weeks, with follow-up after another 4 weeks. The primary endpoints were frequency and intensity of  abdominal pain.

 

weizman-2016

Significant relief in frequency (p<0.02) and severity (p<0.01) of abdominal pain compared to placebo at 4 weeks. Continuously and significantly relieved severity of abdominal pain compared to placebo at 8 weeks. Reduced incidence of perceived abdominal distension and bloating compared to placebo at 4 weeks (p=0.013).

Conclusion
L. reuteri Protectis significantly reduced the frequency and severity of functional abdominal pain in children.

 

Reference

Weizman Z, Abu-Abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2016;174:160-164. 

Crawling baby

For the avoidance of doubt, BioGaia’s products are food supplements, and the information on this part of the website should not be interpreted as our products are intended to diagnose, treat, cure or prevent any disease.

The information on this part of the website is intended only for health care and business professionals. If you are not a health care or business professional and would like to learn more about the indications BioGaia works with, please visit our Expertise pages.

Please read terms & conditions before accepting. By clicking on the button “I acknowledge and accept” you confirm that you are a healthcare or business professional and have read and understood this disclaimer including the terms and conditions.